ArticleCurrent issues in molecular biology2026
Diagnostic Performance of Galectin-1 and Mucin-1 in Uterine Tumors: A Case-Control Study.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesUterine leiomyomas are common benign tumors, whereas uterine sarcomas are rare but aggressive malignancies. Preoperative differentiation among leiomyoma, smooth muscle tumor of uncertain malignant potential (STUMP), and uterine sarcoma remains a major clinical challenge, with diagnosis often established only after histopathological evaluation. The identification of reliable circulating biomarkers could improve preoperative risk stratification and guide surgical decision-making. This study aimed to evaluate the usefulness of galectin-1 and mucin-1 in the diagnosis of uterine tumors. MATERIALS AND
methodsThis prospective, single-center case-control study was conducted at the Third Department of Obstetrics & Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece, between 2013 and 2024. Serum galectin-1 and mucin-1 levels were measured preoperatively using ELISA and electrochemiluminescence immunoassay (ECLIA), respectively. Group comparisons were performed using non-parametric tests. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Multivariable logistic regression was used to assess independent associations with sarcomas/STUMP status.
resultsThe study population comprised 156 women (49 healthy controls, 90 patients with uterine myomas, 8 with STUMP and 9 patients with uterine sarcomas) treated during the study period. Galectin-1 differed significantly across the four histological groups (
conclusionsSerum galectin-1 may have potential as an adjunctive biomarker in the preoperative assessment of uterine tumors, but its modest discrimination and unstable cutoff-dependent performance may preclude its use as a standalone diagnostic test. MUC1 showed limited diagnostic utility in the primary clinical comparison. Given the clinical implications of misdiagnosis, particularly regarding surgical management, further validation in larger cohorts and multimarker approaches are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.